Urban Health Today Editors

Urban Health Today

Patients aged 75-80 did not have significantly increased morbidity or mortality compared with patients 55-65 when undergoing autologous hematopoietic stem cell transplant (HSCT), according to a retrospective <a href="https://ash.confex.com/ash/2021/webprogram/Paper146532.html">study</a> presented at the 2021 American Society of Hematology Annual Meeting.Nearly half of new diagnosed of multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) are in patients over 75 years old. Such patients, due to their advanced age, have been excluded from key clinical trials examining safety and efficacy of auto HSCT.Researchers from Montefiore Medical Center, which serves a minority population, compared short-term outcomes for auto-HSCT in patients aged 75 or older to those of patients aged 55-65 who were diagnosed with MM or NHL. Patients were conditioned with either melphalan or BEAM.The study included 43 patients aged 75 or older and these patients were matched to 43 patients in the younger group by sex and time of transplant.Admission mortality was not significantly different between the two age groups. There was only one death in the control group. The length of stay was also comparable at 18 days for patients 75 and older and 19 days for patients aged 55-65.Time to white blood cell engraftment in the older patients was 12 days compared with 11 days in the younger group (P=0.032). Time to platelet engraftment was 14 days in the older group compared with 12 days in the younger group (P=0.014). Although these were both significantly longer in the older group, the researchers said the clinical significance of this finding is questionable, as this difference did not seem to prolong length of stay. There were no increased rates of neutropenia, 30-day readmission rate, or ICU admissions in the older group.One and five-year survival rates were also similar between the two groups.Based on these data, auto-HSCT for MM and NHL in patients over 75 years old does not carry increased morbidity or mortality, the researchers concluded.

Rebecca Araujo

AI-Driven Insulin Support: Are These Tools Ready for Diabetes Care?

Diabetes

Lou Portero

Heart Rate Complexity May Predict Cognitive Decline in Older Adults

Alzheimer's & Dementia

Female Cancer Survivors Face Higher Rates of Fatigue and Depression, Study Finds

Women's Neurology

Latest News

No Increased Morbidity, Mortality in Older Patients With MM Undergoing Auto-HSCT

Multiple Myeloma

Patients aged 75-80 did not have significantly increased morbidity or mortality compared with patients 55-65 when undergoing autologous hematopoietic stem cell transplant.

No Increased Morbidity, Mortality in Older Patients with MM Undergoing Auto-HSCT

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe